FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
To the Editor: Conroy et al. (May 12 issue) 1 report that FOLFIRINOX (a combination chemotherapy regimen consisting of oxaliplatin, irinotecan, fluorouracil, and leucovorin) provided a statistically and clinically significant benefit over single-agent gemcitabine in patients with advanced pancreatic...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2011-08, Vol.365 (8), p.768-769 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 769 |
|---|---|
| container_issue | 8 |
| container_start_page | 768 |
| container_title | The New England journal of medicine |
| container_volume | 365 |
| creator | Vaccaro, Vanja Sperduti, Isabella Milella, Michele |
| description | To the Editor:
Conroy et al. (May 12 issue)
1
report that FOLFIRINOX (a combination chemotherapy regimen consisting of oxaliplatin, irinotecan, fluorouracil, and leucovorin) provided a statistically and clinically significant benefit over single-agent gemcitabine in patients with advanced pancreatic cancer. Although the increased toxicity associated with this combination therapy may temper enthusiasm, this is the first real advance in such therapy since the introduction of gemcitabine. It has been debated whether gemcitabine-based combination therapies provide any additional benefit, and meta-analyses have reached conflicting conclusions.
2
–
4
A sensitivity analysis of data pooled from seven randomized trials involving 2422 patients in which single-agent . . . |
| doi_str_mv | 10.1056/NEJMc1107627 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_885358480</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2435936061</sourcerecordid><originalsourceid>FETCH-LOGICAL-c346t-8395447b894fe63c10e4fd6975720884bd5795ae697cdd9e7d0fa15f0d9955e83</originalsourceid><addsrcrecordid>eNptkE1Lw0AQhhdRbK3ePEsQj0Z3s98XQUJbK_0QUfAWNptZSDFJ3U0E_73RVvHgXOZleHgHHoROCb4imIvr5fh-YQnBUiRyDw0JpzRmDIt9NMQ4UTGTmg7QUQhr3A9h-hANEqIEI4oN0c1kNZ_MHmfL1Uv0Dj50IZpCZcvW5GUNkWt8tIDWhNa0pY0eTG09fMe0j-CP0YEzrwFOdnuEnifjp_Qunq-ms_R2HlvKRBsrqjljMleaORDUEgzMFUJLLhOsFMsLLjU30F9sUWiQBXaGcIcLrTkHRUfofNu78c1bB6HN1k3n6_5lphSnXDGFe-hyC1nfhODBZRtfVsZ_ZARnX66yv656_GzX2eUVFL_wj5weuNgCVRWyGtbV_z2fRxVspg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>885358480</pqid></control><display><type>article</type><title>FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>ProQuest Central UK/Ireland</source><source>New England Journal of Medicine</source><creator>Vaccaro, Vanja ; Sperduti, Isabella ; Milella, Michele</creator><creatorcontrib>Vaccaro, Vanja ; Sperduti, Isabella ; Milella, Michele</creatorcontrib><description>To the Editor:
Conroy et al. (May 12 issue)
1
report that FOLFIRINOX (a combination chemotherapy regimen consisting of oxaliplatin, irinotecan, fluorouracil, and leucovorin) provided a statistically and clinically significant benefit over single-agent gemcitabine in patients with advanced pancreatic cancer. Although the increased toxicity associated with this combination therapy may temper enthusiasm, this is the first real advance in such therapy since the introduction of gemcitabine. It has been debated whether gemcitabine-based combination therapies provide any additional benefit, and meta-analyses have reached conflicting conclusions.
2
–
4
A sensitivity analysis of data pooled from seven randomized trials involving 2422 patients in which single-agent . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMc1107627</identifier><identifier>PMID: 21864184</identifier><language>eng</language><publisher>United States: Massachusetts Medical Society</publisher><subject><![CDATA[5-Fluorouracil ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Camptothecin - administration & dosage ; Camptothecin - analogs & derivatives ; Chemotherapy ; Clinical trials ; Data processing ; Deoxycytidine - analogs & derivatives ; Deoxycytidine - therapeutic use ; Fluorouracil - administration & dosage ; Gemcitabine ; Humans ; Irinotecan ; Leucovorin - administration & dosage ; Metastases ; Organoplatinum Compounds - administration & dosage ; Oxaliplatin ; Pancreatic cancer ; Pancreatic Neoplasms - drug therapy ; Statistical analysis ; Toxicity]]></subject><ispartof>The New England journal of medicine, 2011-08, Vol.365 (8), p.768-769</ispartof><rights>Copyright © 2011 Massachusetts Medical Society. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c346t-8395447b894fe63c10e4fd6975720884bd5795ae697cdd9e7d0fa15f0d9955e83</citedby><cites>FETCH-LOGICAL-c346t-8395447b894fe63c10e4fd6975720884bd5795ae697cdd9e7d0fa15f0d9955e83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMc1107627$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/885358480?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,2757,2758,26101,27922,27923,52380,54062,64383,64387,72239</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21864184$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Vaccaro, Vanja</creatorcontrib><creatorcontrib>Sperduti, Isabella</creatorcontrib><creatorcontrib>Milella, Michele</creatorcontrib><title>FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>To the Editor:
Conroy et al. (May 12 issue)
1
report that FOLFIRINOX (a combination chemotherapy regimen consisting of oxaliplatin, irinotecan, fluorouracil, and leucovorin) provided a statistically and clinically significant benefit over single-agent gemcitabine in patients with advanced pancreatic cancer. Although the increased toxicity associated with this combination therapy may temper enthusiasm, this is the first real advance in such therapy since the introduction of gemcitabine. It has been debated whether gemcitabine-based combination therapies provide any additional benefit, and meta-analyses have reached conflicting conclusions.
2
–
4
A sensitivity analysis of data pooled from seven randomized trials involving 2422 patients in which single-agent . . .</description><subject>5-Fluorouracil</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Camptothecin - administration & dosage</subject><subject>Camptothecin - analogs & derivatives</subject><subject>Chemotherapy</subject><subject>Clinical trials</subject><subject>Data processing</subject><subject>Deoxycytidine - analogs & derivatives</subject><subject>Deoxycytidine - therapeutic use</subject><subject>Fluorouracil - administration & dosage</subject><subject>Gemcitabine</subject><subject>Humans</subject><subject>Irinotecan</subject><subject>Leucovorin - administration & dosage</subject><subject>Metastases</subject><subject>Organoplatinum Compounds - administration & dosage</subject><subject>Oxaliplatin</subject><subject>Pancreatic cancer</subject><subject>Pancreatic Neoplasms - drug therapy</subject><subject>Statistical analysis</subject><subject>Toxicity</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptkE1Lw0AQhhdRbK3ePEsQj0Z3s98XQUJbK_0QUfAWNptZSDFJ3U0E_73RVvHgXOZleHgHHoROCb4imIvr5fh-YQnBUiRyDw0JpzRmDIt9NMQ4UTGTmg7QUQhr3A9h-hANEqIEI4oN0c1kNZ_MHmfL1Uv0Dj50IZpCZcvW5GUNkWt8tIDWhNa0pY0eTG09fMe0j-CP0YEzrwFOdnuEnifjp_Qunq-ms_R2HlvKRBsrqjljMleaORDUEgzMFUJLLhOsFMsLLjU30F9sUWiQBXaGcIcLrTkHRUfofNu78c1bB6HN1k3n6_5lphSnXDGFe-hyC1nfhODBZRtfVsZ_ZARnX66yv656_GzX2eUVFL_wj5weuNgCVRWyGtbV_z2fRxVspg</recordid><startdate>20110825</startdate><enddate>20110825</enddate><creator>Vaccaro, Vanja</creator><creator>Sperduti, Isabella</creator><creator>Milella, Michele</creator><general>Massachusetts Medical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope></search><sort><creationdate>20110825</creationdate><title>FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer</title><author>Vaccaro, Vanja ; Sperduti, Isabella ; Milella, Michele</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c346t-8395447b894fe63c10e4fd6975720884bd5795ae697cdd9e7d0fa15f0d9955e83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>5-Fluorouracil</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Camptothecin - administration & dosage</topic><topic>Camptothecin - analogs & derivatives</topic><topic>Chemotherapy</topic><topic>Clinical trials</topic><topic>Data processing</topic><topic>Deoxycytidine - analogs & derivatives</topic><topic>Deoxycytidine - therapeutic use</topic><topic>Fluorouracil - administration & dosage</topic><topic>Gemcitabine</topic><topic>Humans</topic><topic>Irinotecan</topic><topic>Leucovorin - administration & dosage</topic><topic>Metastases</topic><topic>Organoplatinum Compounds - administration & dosage</topic><topic>Oxaliplatin</topic><topic>Pancreatic cancer</topic><topic>Pancreatic Neoplasms - drug therapy</topic><topic>Statistical analysis</topic><topic>Toxicity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vaccaro, Vanja</creatorcontrib><creatorcontrib>Sperduti, Isabella</creatorcontrib><creatorcontrib>Milella, Michele</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vaccaro, Vanja</au><au>Sperduti, Isabella</au><au>Milella, Michele</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2011-08-25</date><risdate>2011</risdate><volume>365</volume><issue>8</issue><spage>768</spage><epage>769</epage><pages>768-769</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><abstract>To the Editor:
Conroy et al. (May 12 issue)
1
report that FOLFIRINOX (a combination chemotherapy regimen consisting of oxaliplatin, irinotecan, fluorouracil, and leucovorin) provided a statistically and clinically significant benefit over single-agent gemcitabine in patients with advanced pancreatic cancer. Although the increased toxicity associated with this combination therapy may temper enthusiasm, this is the first real advance in such therapy since the introduction of gemcitabine. It has been debated whether gemcitabine-based combination therapies provide any additional benefit, and meta-analyses have reached conflicting conclusions.
2
–
4
A sensitivity analysis of data pooled from seven randomized trials involving 2422 patients in which single-agent . . .</abstract><cop>United States</cop><pub>Massachusetts Medical Society</pub><pmid>21864184</pmid><doi>10.1056/NEJMc1107627</doi><tpages>2</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2011-08, Vol.365 (8), p.768-769 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_journals_885358480 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; ProQuest Central UK/Ireland; New England Journal of Medicine |
| subjects | 5-Fluorouracil Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Camptothecin - administration & dosage Camptothecin - analogs & derivatives Chemotherapy Clinical trials Data processing Deoxycytidine - analogs & derivatives Deoxycytidine - therapeutic use Fluorouracil - administration & dosage Gemcitabine Humans Irinotecan Leucovorin - administration & dosage Metastases Organoplatinum Compounds - administration & dosage Oxaliplatin Pancreatic cancer Pancreatic Neoplasms - drug therapy Statistical analysis Toxicity |
| title | FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T04%3A22%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=FOLFIRINOX%20versus%20Gemcitabine%20for%20Metastatic%20Pancreatic%20Cancer&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Vaccaro,%20Vanja&rft.date=2011-08-25&rft.volume=365&rft.issue=8&rft.spage=768&rft.epage=769&rft.pages=768-769&rft.issn=0028-4793&rft.eissn=1533-4406&rft_id=info:doi/10.1056/NEJMc1107627&rft_dat=%3Cproquest_cross%3E2435936061%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=885358480&rft_id=info:pmid/21864184&rfr_iscdi=true |